Long-acting microsphere and lipid nanoparticle (LNP) injection R&D and manufacturing platform company Inventage Lab (CEO Kim Joo-hee) is an innovative self-developed new drug developed by the US Patent Office (US PTO) for long-acting injections -active for the treatment of autoimmune diseases. ) on the 30th that he had received the patent decision.
The patent registered this time has proven its originality in the ‘Drug Rediscovery Programme’, a self-developed strategy to discover indications for new mechanisms based on previously approved active pharmaceutical ingredients (APIs) This is the patent property first.
The drug rediscovery program is being conducted based on the company’s long-acting injection development platform ‘IVL-DrugFluidic’. For drugs that require long-term use for chronic diseases such as autoimmune diseases, one injection maintains drug effectiveness for 1 to 3 months with high medication convenience and stable drug release function by Inventage Lab’s unique formulation technology. The company explained that it has a. distinguishing from the discovery of new indications of general oral drugs by minimizing side effects and maximizing efficacy.
The company added that, through this patent registration, it has expanded its development scope to an innovative new drug pipeline with high added value for autoimmune diseases, following the long-standing IMD pipeline, which has been characterized by changing the route of administration and making the best of release control. .
Autoimmune diseases include rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn’s disease, type 1 diabetes, alopecia areata, etc. Currently, it forms a market of more than 200 trillion won worldwide.
However, among existing treatments, low molecular compound treatments have limitations due to side effects and variable tolerability. In addition, in the case of new biopharmaceuticals, despite their improved effectiveness, there are problems such as expensive treatment costs, development of resistance, and limitations in medication compliance due to frequent injections, so new treatment options are still needed. increasing safety and effectiveness It is a high treatment area.
Inventage Lab is currently developing treatment drugs for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Currently, the non-clinical efficacy test and the toxicity test for early clinical entry have been completed. In particular, in the case of multiple sclerosis, it was designated as an orphan drug by the Ministry of Food and Drug Safety in November last year, and rapid clinical development is possible.
Kim Joo-hee, CEO of Inventage Lab, said, “This patent registration is significant as it has laid the foundation for commercialization, such as expanding indications with creative development strategies by promoting drug delivery platform technology.” “We will pursue the convenience of patients suffering from incurable diseases by developing innovative new drugs by expanding and growing them into blockbuster new drugs that can be used in the global market.”
